RT Journal Article
SR Electronic
T1 Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.25.20154252
DO 10.1101/2020.08.25.20154252
A1 Bermejo-Martin, Jesús F
A1 González-Rivera, Milagros
A1 Almansa, Raquel
A1 Micheloud, Dariela
A1 Tedim, Ana P.
A1 Domínguez-Gil, Marta
A1 Resino, Salvador
A1 Martín-Fernández, Marta
A1 Murua, Pablo Ryan
A1 Pérez-García, Felipe
A1 Tamayo, Luis
A1 Lopez-Izquierdo, Raúl
A1 Bustamante, Elena
A1 Aldecoa, César
A1 Gómez, José Manuel
A1 Rico-Feijoo, Jesús
A1 Orduña, Antonio
A1 Méndez, Raúl
A1 Fernández Natal, Isabel
A1 Megías, Gregoria
A1 González-Estecha, Montserrat
A1 Carriedo, Demetrio
A1 Doncel, Cristina
A1 Jorge, Noelia
A1 Ortega, Alicia
A1 de la Fuente, Amanda
A1 del Campo, Félix
A1 Fernández-Ratero, José Antonio
A1 Trapiello, Wysali
A1 González-Jiménez, Paula
A1 Ruiz, Guadalupe
A1 Kelvin, Alyson A.
A1 Ostadgavahi, Ali Toloue
A1 Oneizat, Ruth
A1 María Ruiz, Luz
A1 Miguéns, Iria
A1 Gargallo, Esther
A1 Muñoz, Ioana
A1 Pelegrin, Sara
A1 Martín, Silvia
A1 García Olivares, Pablo
A1 Cedeño, Jamil Antonio
A1 Albi, Tomás Ruiz
A1 Puertas, Carolina
A1 Ángel Berezo, Jose
A1 Renedo, Gloria
A1 Herrán, Rubén
A1 Bustamante-Munguira, Juan
A1 Enríquez, Pedro
A1 Cicuendez, Ramón
A1 Blanco, Jesús
A1 Abadia, Jesica
A1 Barquero, Julia Gómez
A1 Mamolar, Nuria
A1 Blanca-López, Natalia
A1 Valdivia, Luis Jorge
A1 Caso, Belén Fernández
A1 Mantecón, María Ángeles
A1 Motos, Anna
A1 Fernandez-Barat, Laia
A1 Ferrer, Ricard
A1 Barbé, Ferrán
A1 Torres, Antoni
A1 Menéndez, Rosario
A1 Eiros, José María
A1 Kelvin, David J
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.08.25.20154252.abstract
AB Background COVID-19 can course with respiratory and extrapulmonary disease. SARS-CoV-2 RNA is detected in respiratory samples but also in blood, stool and urine. Severe COVID-19 is characterised by a dysregulated host response to this virus. We studied whether viral RNAemia or viral RNA load in plasma are associated to severe COVID-19 and also to this dysregulated response.Methods 250 patients with COVID-19 were recruited (50 outpatients, 100 hospitalised ward patients, and 100 critically ill). Viral RNA detection and quantification in plasma was performed using droplet digital PCR, targeting the N1 and N2 regions of the SARS-CoV-2 nucleoprotein gene. The association between SARS-CoV-2 RNAemia and viral RNA load in plasma with severity was evaluated by multivariate logistic regression. Correlations between viral RNA load and biomarkers evidencing dysregulation of host response were evaluated by calculating the Spearman correlation coefficients.Results the frequency of viral RNAemia was higher in the critically ill patients (78%) compared to ward patients (27%) and outpatients (2%) (p<0.001). Critical patients had higher viral RNA loads in plasma than non-critically ill patients, with non survivors showing the highest values. When outpatients and ward patients were compared, viral RNAemia did not show significant associations in the multivariate analysis. In contrast, when ward patients were compared with ICU patients, both viral RNAemia and viral RNA load in plasma were associated with critical illness (OR [CI 95%], p): RNAemia (3.92 [1.183 - 12.968], 0.025), viral RNA load (N1) (1.962 [1.244 - 3.096], 0.004); viral RNA load (N2) (2.229 [1.382 - 3.595], 0.001). Viral RNA load in plasma correlated with higher levels of chemokines (CXCL10, CCL2), biomarkers indicative of a systemic inflammatory response (IL-6, CRP, Ferritin), activation of NK cells (IL-15), endothelial dysfunction (VCAM-1, angiopoietin-2, ICAM-1), coagulation activation (D-Dimer and INR), tissue damage (LDH, GPT), neutrophil response (neutrophils counts, myeloperoxidase, GM-CSF) and immunodepression (PD-L1, IL-10, lymphopenia and monocytopenia).Conclusions SARS-CoV-2 RNAemia and viral RNA load in plasma are associated to critical illness in COVID-19. Viral RNA load in plasma correlates with key signatures of dysregulated host responses, suggesting a major role of uncontrolled viral replication in the pathogenesis of this disease.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04457505Funding StatementThis work was supported by awards from the Canadian Institutes of Health Research, the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding initiative (CIHR OV2 170357), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK), Li-Ka Shing Foundation (DJK), Dalhousie Medical Research Foundation (DJK), the Subvenciones de concesion directa para proyectos y programas de investigacion del virus SARS-CoV2, causante del COVID-19, FONDO - COVID19, Instituto de Salud Carlos III (COV20/00110, CIBERES, 06/06/0028), (AT) and finally by the Convocatoria extraordinaria y urgente de la Gerencia Regional de Salud de Castilla y Leon, para la financiacion de proyectos de investigacion en enfermedad COVID-19 (GRS COVID 53/A/20) (CA). DJK is a recipient of the Canada Research Chair in Translational Vaccinology and Inflammation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Etica de la Investigacion con Medicamentos del Area de Salud de Salamanca, code PI 2020 03 452All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable requestSARS-CoV-2Severe acute Respiratory Syndrom-Coronavirus-2LDHLactate dehydrogenaseSFGranulocyte colony-stimulating factorTLRtoll like receptor